Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Goldblum

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|May 31, 2018
Minimal clinically important difference (MCID) for work productivity and activity impairment (WPAI) questionnaire in psoriasis patientsJ J Wu, C Lin, L Sun, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2011
Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVEJ-P Ortonne, S Chimenti, K Reich, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 20, 2015
Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasisR G Langley, P Rich, A Menter, et al.
The British Journal of Dermatology|August 18, 2012
Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trialB E Strober, J M Sobell, K C Duffin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 3, 2016
Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3P van de Kerkhof, L Guenther, A B Gottlieb, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of the European Academy of Dermatology and Venereology : JEADV|May 31, 2018
Minimal clinically important difference (MCID) for work productivity and activity impairment (WPAI) questionnaire in psoriasis patientsJ J Wu, C Lin, L Sun, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2011
Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVEJ-P Ortonne, S Chimenti, K Reich, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 20, 2015
Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasisR G Langley, P Rich, A Menter, et al.
The British Journal of Dermatology|August 18, 2012
Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trialB E Strober, J M Sobell, K C Duffin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 3, 2016
Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3P van de Kerkhof, L Guenther, A B Gottlieb, et al.
Pageof 1